Management of treatment-related adverse events in patients with multiple myeloma

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 2, 2010, Pages

  Mateos, María Victoria ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Adverse events; Bortezomib; Gastrointestinal disturbances; Lenalidomide; Multiple myeloma; Myelosuppression; Peripheral neuropathy; Somnolence; Thalidomide; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; LAXATIVE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; THALIDOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VINCRISTINE; WARFARIN;

AGE DISTRIBUTION; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER RELAPSE; CANCER RISK; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; ENTEROPATHY; EXERCISE; FATIGUE; FEBRILE NEUTROPENIA; FLUID INTAKE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEMATOLOGIC DISEASE; HERPES ZOSTER; HIGH FIBER DIET; HUMAN; HYPERCALCEMIA; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; PATIENT MONITORING; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PREGNANCY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REFRACTORY PERIOD; SALVAGE THERAPY; SKIN ATROPHY; SKIN TOXICITY; SOCIAL SUPPORT; SOMNOLENCE; SPINAL CORD COMPRESSION; TERATOGENICITY; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING; WEAKNESS; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISORDERS OF EXCESSIVE SOMNOLENCE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; THALIDOMIDE; VENOUS THROMBOEMBOLISM;

EID: 77952817334     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70009-8     Document Type: Article

References (83)

1. Brenner H, Gondos A, Pulte D Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
3. Brenner H, Gondos A, Pulte D Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009, 94:270-275.
4. Gleason C, Nooka A, Lonial S Supportive therapies in multiple myeloma. J Natl Compr Canc Netw 2009, 7:971-979.
5. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006, 132:584-593.
6. Chiou TJ, Wang TH, Chao TY, et al. Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Invest 2007, 25:140-147.
7. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431-436.
8. Ludwig H, Hajek R, Tóthová E, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009, 113:3435-3442.
9. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008, 26:2171-2177.
10. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367:825-831.
11. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008, 112:3107-3114.
12. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009, 27:3664-3670.
13. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
14. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
15. Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004, 15:134-138.
16. von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008, 81:247-252.
17. García-Sanz R, González-Porras JR, Hernández JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004, 18:856-863.
18. Offidani M, Corvatta L, Polloni C, et al. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br J Haematol 2009, 144:653-659.
19. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009, 27:1788-1793.
20. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289-3294.
21. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
22. Morgan GJ, Davies FE, Gregory WM, et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS [abstract]. Blood 2009, 114. abstract 352.
23. Kannarkat G, Lasher EE, Schiff D Neurologic complications of chemotherapy agents. Curr Opin Neurol 2007, 20:719-725.
24. Schiff D, Wen PY, van den Bent MJ Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009, 6:596-603.
25. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006, 24:4507-4514.
26. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007, 69:573-581.
27. Zara G, Ermani M, Rondinone R, Arienti S, Doria A Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry 2008, 79:1258-1261.
28. Reddy GK, Mughal TI, Lonial S Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma. Support Cancer Ther 2006, 4:19-22.
29. Tariman JD, Love G, McCullagh E, Sandifer S, IMF Nurse Leadership Board Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008, 12(3 Suppl):29-36.
30. van Marion AM, Auwerda JJ, Lisman T, et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008, 32:1078-1084.
31. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001, 98:1614-1615.
32. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22:414-423.
33. Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis 2007, 18:595-598.
34. Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004, 18:2044-2046.
35. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004, 126:715-721.
36. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005, 80:1568-1574.
37. Niesvizky R, Martínez-Baños D, Jalbrzikowski J, et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007, 48:2330-2337.
38. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008, 111:3968-3977.
39. Ghobrial IM, Rajkumar SV Management of thalidomide toxicity. J Support Oncol 2003, 1:194-205.
40. Gay F, Palumbo A Multiple myeloma: management of adverse events. Med Oncol 2009, 10.1007/s12032-009-9262-4.
41. Mateos MV, Oriol A, Martínez J, et al. Bortezomib (velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent? [abstract]. Blood 2008, 112. abstract 651.
42. Mateos MV, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years [abstract]. Blood 2009, 114. abstract 3.
43. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
44. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006, 108:3458-3464.
45. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009, 114:772-778.
46. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106:4050-4053.
47. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37.
48. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol 2007, 25:4459-4465.
49. Palumbo A, Falco P, Falcone A, et al. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymphoma Myeloma 2009, 9:145-150.
50. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008, 111:1101-1109.
51. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
52. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
53. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009, 146:164-170.
54. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009, 23:605-607.
55. Morgan GJ, Schey SA, Wu P, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007, 137:268-269.
56. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006, 17:1766-1771.
57. Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009, 113:4137-4143.
58. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008, 112:4445-4451.
59. Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009, 82:426-432.
60. Schey S, Morgan GJ, Ramasamy K, et al. CRD: a phase 1 dose escalation study to determine the maximum tolerated dose of cyclophosphamide in combination with lenalidomide and dexamethasone in relapsed/refractory myeloma [abstract]. Blood 2008, 112. abstract 3707.
61. Hirsh J Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 2007, 131:275-277.
62. Palumbo A, Dimopoulos M, San Miguel J, et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev 2009, 23:87-93.
63. Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007, 138:640-643.
64. Revlimid prescribing information [2009] [accessed 18 March 2010]. http://www.revlimid.com/pdf/REVLIMID_PI.pdf.
65. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127:165-172.
66. Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008, 143:537-540.
67. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
68. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007, 137:429-435.
69. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110:3557-3560.
70. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005, 129:776-783.
71. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
72. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
73. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008, 112:1529-1537.
74. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006, 91:929-934.
75. Richardson P, Jagannath S, Colson K Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clin Adv Hematol Oncol 2006, 4:1.
76. Argyriou AA, Iconomou G, Kalofonos HP Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112:1593-1599.
77. Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 2010, 34:471-474.
78. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007, 110:1042-1049.
79. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009, 27:3518-3525.
80. Lonial S, Multiple Myeloma Research Foundation Management of toxicities associated with bortezomib. Oncology (Williston Park) 2006, 20:1592-1593. 1597.
81. San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22:842-849.
82. Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008, 49:890-895.
83. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008, 26:4784-4790.